Moderna

Earlier today, Moderna reported financial results and provided business updates for the second quarter of 2025. Members of our executive team sat down to provide more insight into our financial performance and upcoming late-stage pipeline milestones. Watch now: https://lnkd.in/enWMWtsT

Today, we reported financial results and provided business updates for the second quarter of 2025. Read more: https://lnkd.in/eA5bnSRQ

Today we announced that the UK Court of Appeal has upheld the validity of our EP’949 patent. Read more: https://lnkd.in/ezPPMm6s

Today we announced that the European Commission has granted marketing authorization for the updated formulation of our COVID-19 vaccine Spikevax®, targeting the SARS-CoV-2 variant LP.8.1, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals six months of age and older.    This marketing authorization follows the Positive Opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use.   Read more: https://lnkd.in/e2ZDqTS5

Today we announced that three abstracts on our investigational mRNA therapeutics have been accepted for presentation at the 2025 European Society for Medical Oncology (ESMO) Congress, which will be held October 17-21, 2025, in Berlin, Germany. Read more: https://lnkd.in/egqK_X5h

Today we announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending marketing authorization for an updated formulation of the COVID-19 vaccine Spikevax®, targeting the SARS-CoV-2 variant LP.8.1, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals six months of age and older.   Read more: https://lnkd.in/ejxV-jqJ

For Jagjit Ludu, joining Moderna meant the chance to think differently and connect science to people in new ways. From launching clinician-focused docu-series to building AI-powered tools for bite-sized learning, he’s reshaping how Medical Affairs engages and informs. 💡 “Being a changemaker means hearing ‘no’ and persisting,” Jagjit shares. His work is proof that creativity and science can move together—and make an impact. Read more about Jagjit’s journey: https://lnkd.in/eex_9nSs

We are proud to have earned a top score on Disability:IN’s 2025 Disability Index and to be recognized for #DisabilityInclusion for the 4th year in a row! 🏆    Leading with belonging is essential to helping our people thrive. Thank you Disability:IN for this recognition and for your ongoing leadership in advancing disability inclusion across the business community. 

Today we announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Application for Spikevax®, our COVID-19 vaccine, in children 6 months through 11 years of age who are at increased risk for COVID-19 disease. Our COVID-19 vaccine, mRNA-1273, was previously available for pediatric populations under Emergency Use Authorization.    Read more: https://lnkd.in/dxEgzjY9

Congratulations to our Chief Legal Officer, Shannon Thyme Klinger, on this well-deserved recognition. Shannon’s bold leadership and deep commitment to patients continues to inspire our teams and shape the future of medicine across Moderna and our industry.